Evidence map›Paper›PMID 39247981›Full record

ArticleHuman vaccines & immunotherapeutics2024

Time interval distribution of hepatitis B vaccine immunization among infants in China from 2017 to 2021.

Sihui Zhang, Xiaoling Tian, Li Wang, Ming Liu, Chao Wang, Tianshuo Zhao, Xianming Cai, Xiyu Zhang, Mingting Wang, Juan Du and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sihui ZhangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, P. R. China.
Xiaoling TianInstitute for Immunization and Prevention, Inner Mongolia Center for Disease Control and Prevention, Hohhot City, People's Republic of China.
Li WangInstitute for Immunization and Prevention, Suzhou Center for Disease Control and Prevention, Suzhou, China.
Ming LiuDepartment of Infectious Disease, Guizhou Provincial Center for Disease Control and Prevention, Guiyang, China.
Chao WangDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.
Tianshuo ZhaoDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, P. R. China.
Xianming CaiDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, P. R. China.
Xiyu ZhangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, P. R. China.
Mingting WangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, P. R. China.
Juan DuDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.
Yaqiong LiuDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.
Qingbin LuDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.
Jiang WuInstitute for Immunization and Prevention, Beijing Center for Disease Prevention and Control, Beijing Research Center for Preventive Medicine, Beijing, China.
Ninghua HuangDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.
Fuqiang CuiDepartment of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infant hepatitis B vaccine coverage in China is high, with over 95% of infants immunized; however, high vaccine coverage can often mask low timeliness. The vaccination interval between the second and third doses is not clearly defined by immunization guidelines in China. This retrospective cohort study assessed the time interval distribution of hepatitis B vaccination among a cohort of randomly selected live births from the Centers for Disease Control and Prevention across four provinces or municipalities in China between January 2017 and December 2021. Among the infants analyzed, 163,224 received the first dose of hepatitis B vaccine with 146,905 (90.0%) and 135,757 (83.2%) infants receiving the second and third doses, respectively. A total of 132,577 (90.2%) infants received the second dose between 28 and 61 days after the first dose. Of the 119,437 (88.0%) infants that completed the hepatitis B series between 61 and 214 days after the second dose 87,067 (64.1%) infants were vaccinated with the third dose between 151 and 180 days after the second dose. The time interval distribution varied across the four provinces or municipalities (

Indexed as

Hepatitis BHepatitis B VaccinesImmunization ScheduleVaccination CoverageChinaFemaleHumansInfantInfant, NewbornMaleRetrospective StudiesTime FactorsVaccinationHepatitis B Vaccineshepatitis B vaccinationinfantslast two doseTime intervaltype of vaccine

Identifiers

PMID39247981
PMCPMC11385157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.